Millions of Americans still pop a low‑dose "baby" aspirin every morning, betting it will protect their hearts and maybe even fend off cancer. But fresh evidence says that for the average person, daily aspirin is no quick fix against colorectal (bowel) cancer, and the downsides show up right away. Baltimore physicians and national experts now say anyone eyeing aspirin for cancer prevention should slow down and weigh the pros and cons with a clinician first.
What the new review found
In a sweeping analysis of 10 randomized trials involving 124,837 participants, researchers concluded that aspirin "probably does not reduce the risk of bowel cancer in the first 5 to 15 years of use." They also found no suitable randomized trials for non‑aspirin NSAIDs and warned that any hint of benefit that might appear after a decade or more is uncertain. "This benefit is not guaranteed and comes with immediate risks," the authors reported, according to Cochrane.
Bleeding risk outweighs early cancer protection for many
One of the biggest red flags comes from a large randomized trial of mostly older adults known as ASPREE. In that study, people assigned to daily low‑dose aspirin had a statistically significant 38% increase in intracranial bleeding, without a meaningful drop in ischemic stroke. That pattern, echoed by other data, helped drive updated guidance that puts a spotlight on the immediate risk of major bleeding.
A secondary analysis of ASPREE and related evidence makes it clear that bleeding harms typically begin right away, while any cancer protection would take years to show up, according to JAMA Network Open.
Who might still benefit
The new Cochrane review zeroed in on average‑risk people, so it does not overturn evidence that some high‑risk groups can still benefit. Individuals with certain hereditary syndromes, especially Lynch syndrome, appear to gain meaningful protection from aspirin.
Large trials in people with Lynch syndrome have shown a clear reduction in colorectal cancer risk, and newer work suggests low‑dose aspirin may cut that risk roughly in half for some carriers, though experts are still debating the ideal dose. For a deeper look at those findings and how they might influence care for families with Lynch syndrome, see reporting from Cancer Research UK.
What doctors are telling patients
Clinicians stress that this is a moment for conversation, not solo decision‑making in the medicine cabinet. People already taking aspirin for heart disease or stroke prevention are being urged not to stop suddenly but to check in with their clinician first. Meanwhile, those thinking about starting daily aspirin purely to lower colorectal cancer risk are being told to ask before they act.
Recent coverage in The Baltimore Sun underscores that message, noting local physicians are pushing for personalized risk‑benefit talks that factor in age, heart risk, and bleeding history.
Practical steps for readers
If you are worried about colorectal cancer, the most reliable tools are still the unglamorous ones: regular screening and everyday lifestyle choices like quitting smoking, staying physically active, and maintaining a healthy weight. None of that fits neatly in a pill bottle, but it is where the strongest evidence lies.
If aspirin is already in your routine or on your radar, bring a full medication list plus your cardiovascular and bleeding risk factors to your next primary care visit so your clinician can run the numbers and talk through tradeoffs. Guidance from the U.S. Preventive Services Task Force frames aspirin use as an individualized decision and notes that people already on it for cardiac reasons usually should keep taking it unless their clinician advises otherwise.
Bottom line: for most average‑risk adults, the new Cochrane analysis suggests daily aspirin is not a dependable cancer‑prevention shortcut and carries real short‑term bleeding risks, while certain high‑risk groups can still benefit under medical supervision. If aspirin is part of your daily habit or your prevention wish list, it is time to talk with your clinician. Screening and risk‑reduction measures remain the frontline defense against colorectal cancer.
